-- Days : -- HRS : -- MIN : -- SEC
Register Now →
|Articles|April 15, 2008

The American Journal of Managed Care

  • April 2008
  • Volume 14
  • Issue 4

Furst DE, Khanna D. (Am J Manag Care. 2007;13[suppl 9]:S216-S217.

After the publication of our December 2007 supplement, “Health-related Quality of Life in Rheumatoid Arthritis,” the Editors learned that several authors were not given the opportunity to review the final proofs of their manuscripts. As a result, the following errors were subsequently identified. First, the co-author’s name was inadvertently omitted from the Introduction. The correct byline for the Introduction should read: Daniel E. Furst, MD, and Dinesh Khanna, MD.

Second, in the article “Generic Quality-of-life Assessment in Rheumatoid Arthritis,” by Tugwell, et al (Am J Manag Care. 2007;13[suppl 9]:S224-S236), some of the indicators for Health Dimension and Psychometric Properties were missing from Table 1; some data in Table 3 were incorrect; and the reference numbers in Figures 1a and 1b were misnumbered. The corrected tables and figures appear on the following pages (see pages 235-238).

Finally, due to the extent of the errors in the article by Strand et al, “Improved Health-related Quality of Life With Effective Disease-modifying Antirheumatic Drugs: Evidence From Randomized Controlled Trials,” we are reprinting a corrected version of this article in this issue (see pages 239-253).


Related to this article

Kenneth Komorny, PharmD, BCPS | Image: Moffitt Cancer Center
At a Stakeholder Interchange convened by The American Journal of Managed Care® in Tampa, Florida, an academic-community mix of hematologist-oncologists and pharmacists debated prior authorization, site-of-care payment disparities, and how aggressively to push bispecific antibody regimens to community practices treating patients with relapsed/refractory multiple myeloma.
Andrew D. Zelenetz, MD, PhD, is the chair of the NCCN B-cell Lymphomas panel.  | Image: LinkedIn
The National Comprehensive Cancer Network update on mantle cell lymphoma puts covalent BTK inhibitors, MRD testing, and TP53 sequencing at the center of frontline care, while adding pirtobrutinib and a pair of CAR T-cell therapies for disease that progresses on a BTK inhibitor.